In the U.S., a supplemental Biologics License Application (sBLA) has been accepted for review seeking approval for Dupixent in certain children aged 2 to 11 years with CSU. The U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results